Nicox (LTS:0RCQ) Operating Cash Flow per Share : €-0.17 (TTM As of Jun. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Nicox Operating Cash Flow per Share?

Nicox's operating cash flow per share for the six months ended in Jun. 2024 was €0.00. Nicox's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.17.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Nicox's Operating Cash Flow per Share or its related term are showing as below:

During the past 13 years, Nicox's highest 3-Year average Operating Cash Flow per Share Growth Rate was 49.50% per year. The lowest was -866.60% per year. And the median was 4.50% per year.

LTS:0RCQ's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

Nicox Operating Cash Flow per Share Historical Data

The historical data trend for Nicox's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Operating Cash Flow per Share Chart

Nicox Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.53

-0.16

-0.49

-0.46

Nicox Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.24	-0.25	-0.17	-	-

Competitive Comparison of Nicox's Operating Cash Flow per Share

For the Biotechnology subindustry, Nicox's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nicox's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Nicox's Price-to-Operating-Cash-Flow falls into.

Nicox Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Nicox's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	0	/	49.859
	=	0.00

Nicox's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Jun. 2024 )	=	Cash Flow from Operations (Q: Jun. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2024 )
	=	0	/	63.144
	=	0.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.17

Nicox Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Nicox's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Nicox Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (LTS:0RCQ) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

NICXF:USA ALCOX:France NXOA:Germany NXOA:Germany

Address

Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410

Website

https://www.nicox.com

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines